Current treatments for lung cancer employ immunotherapy, often in combination with chemotherapy. However, benefits to patients remain slight. In a preclinical study (“Overcoming ...

BUFFALO, NY- October 1, 2024 – A new mini review was published in Oncotarget's Volume 15 on September 30, 2024, entitled, “Linking FOXM1 and PD-L1 to CDK4/6-MEK targeted therapy resistance in ...

--MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T cell ...

Despite compelling antitumour activity of antibodies targeting the programmed death 1 (PD-1): programmed death ligand 1 (PD-L1) immune checkpoint in lung cancer, resistance to these therapies has ...

0-69 days: 116 patient samples. 70-99 days: 52 samples. 100-746 days: 254 samples. No pre-biopsy vaccine: 1984 samples. There were no significant differences in histology, clinical stage, sex, or ...